CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine

References

• Friedlander AM, Brachman PS. Anthrax. In: Vaccines, Plotkin SA, Mortimer EA (Eds),WB Saunders, PA, USA, 729–739 (1998).
   Google Scholar
• Quinn CP, Turnbull PC. 98 AD anthrax. In: Topley and Wilson's Microbiology and Microbial Infections, Ballow M, Sussman M (Eds), Collier, London, UK, 799–818 (1998).
   Google Scholar
• Lane HC, Montagne JL, Fauci AS. Bioterrorism: a clear and present danger. Nat. Med.7, 1271–1273 (2001).
   PubMed Web of Science ®Google Scholar
• Ivins BE, Welkos SL, Liffle SF, Crumrine MH, Nelson GO. Immunization against anthrax with Bacilus anthracis protective antigen combined with adjuvants. Infect. Immun.60, 662–668 (1992).
   PubMed Web of Science ®Google Scholar
• Welkos SL, Friedlander AM. Comparative safety and efficacy against Bacilus anthracis of protective antigen and live vaccines in mice. Microb. Pathog.5, 127–139 (1988).
   PubMed Web of Science ®Google Scholar
• Little SF, Ivins BE. Molecular pathogenesis of Bacilus anthracis infection. Microbes Infect.1, 131–139 (1999).
   PubMed Web of Science ®Google Scholar
• Welkos S, Little S, Friedlander A, Fritz D, Fellows P. The role of antibodies to Bacilus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology147, 1677–1685 (2001).
   PubMedGoogle Scholar
• Ivins BE, Welkos SL. Recent advances in the development of an improved, human anthrax vaccine. Eur. J. Epidemiol. 4, 12–19 (1988).
   PubMed Web of Science ®Google Scholar
• Ivins BE, Welkos SL, Knudson GB, Little SF. Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacilus anthracis that produce anthrax protective antigen. Infect. Immun.58, 303–308 (1990).
   PubMed Web of Science ®Google Scholar
• Pittman PR, Gibbs PH, Cannon TL, Friedlander AM. Anthrax vaccine: short-term safety experience in humans. Vaccine20, 972–978 (2001).
   PubMed Web of Science ®Google Scholar
• Pittman PR, Kim-Ahn G, Pifat DY et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine20, 1412–1420 (2002).
   PubMed Web of Science ®Google Scholar
• Geier DA, Geier MR. Anthrax vaccination and joint related adverse reactions in light of biological warfare scenarios. Clin. Exp. Rheumatol.20, 217–220 (2002).
   Google Scholar
• Ready T. US soldiers refuse to fall in line with anthrax vaccination scheme. Nat. Med.10, 112 (2004).
   PubMed Web of Science ®Google Scholar
• Davis HL, Suparto II, Weeratna RR et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine18, 1920–1924 (2000).
   PubMed Web of Science ®Google Scholar
• Jones TR, Obaldia N, Gramzinski RA et al. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenic vaccine in Aotus monkeys. Vaccine17, 3065–3071 (1999).
   PubMed Web of Science ®Google Scholar
• Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, Klinman DM. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J. Immunol.168, 1659–1663 (2002).
   PubMed Web of Science ®Google Scholar
• Kreig AM, Yi A, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature374, 546–548 (1995).
   PubMed Web of Science ®Google Scholar
• Klinman DM, Yi A, Beaucage SL, Conover J, Krieg AM. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFNγ. Proc. Natl Acad. Sci. USA93, 2879–2883 (1996).
   PubMed Web of Science ®Google Scholar
• Takeshita F, Leifer CA, Gursel I et al. Cutting edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol.167, 3555–3558 (2001).
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature408, 740–745 (2000).
   Google Scholar
• Ballas ZD, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol.157, 1840–1847 (1996).
   PubMed Web of Science ®Google Scholar
• Halphern MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine interferon-γ production by stimulation of IL-12 and tumor necrosis factor-α. Cell. Immunol.167, 72–78 (1996).
   PubMedGoogle Scholar
• Klinman DM. Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense Nuc. Acid Drug Dev.8, 181–184 (1998).
   PubMedGoogle Scholar
• Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol.27, 2340–2344 (1997).
   PubMed Web of Science ®Google Scholar
• Davis HL. Use of CpG DNA for enhancing specific immune responses. Curr. Top. Microbiol. Immunol.247, 171–184 (2000).
   PubMed Web of Science ®Google Scholar
• Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine16, 1216–1224 (1998).
   PubMed Web of Science ®Google Scholar
• Kreig AM, Davis HL. Enhancing vaccines with immune stimulatory CpG DNA. Curr. Opin. Mol. Ther.3, 15–24 (2001).
   PubMedGoogle Scholar
• Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl Acad. Sci. USA97, 811–816 (2000).
   PubMed Web of Science ®Google Scholar
• Singh M, Ott G, Kazzaz J et al. Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA. Pharm. Res.18, 1476–1479 (2001).
   PubMed Web of Science ®Google Scholar
• Singh M, Kazzaz J, Ugozzoli M, Chesko J, O'Hagan DT. Charged polylactide co-glycolide microparticles as antigen delivery systems. Expert Opin. Biol. Ther.4, 483–491 (2004).
   PubMed Web of Science ®Google Scholar
• Singh M, Li XM, McGee JP et al. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine15, 475–481 (1997).
   PubMed Web of Science ®Google Scholar
• Briones M, Singh M, Ugozzoli M et al. The preparation, characterization, evaluation of cationic microparticles for DNA vaccine delivery. Pharm. Res.18, 709–712 (2001).
   PubMed Web of Science ®Google Scholar
• Denis-Mize KS, Dupuis M, Singh M et al. Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell Immunol. 225, 12–20 (2003).
   PubMed Web of Science ®Google Scholar
• Denis-Mize KS, Dupuis M, MacKichan ML et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther.7, 2105–2112 (2000).
   PubMed Web of Science ®Google Scholar
• O'Hagan D, Singh M, Ugozzoli M et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J. Virol.75, 9037–9043 (2001).
   PubMed Web of Science ®Google Scholar
• Xie H, Gursel I, Ivins BE et al. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect. Immun.73, 828–833 (2005).
   PubMed Web of Science ®Google Scholar
• Bauer M, Heeg K, Wagner H, Lipford GB. DNA activates human immune cells through a CpG sequence-dependent manner. Immunology97, 699–705 (1999).
   PubMed Web of Science ®Google Scholar
• Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol.164, 944–952 (2000).
   PubMed Web of Science ®Google Scholar
• Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J. Immunol.166, 2372–2377 (2001).
   PubMed Web of Science ®Google Scholar
• Klinman DM, Xie H, Little SF, Currie D, Ivins BE. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine22, 2881–2886 (2004).
   PubMed Web of Science ®Google Scholar
• Leifer CA, Verthelyi D, Klinman DM. Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides. J. Immunother.26, 313–319 (2003).
   PubMedGoogle Scholar
• Vajdy M, O'Hagan DT. Microparticles for intranasal immunization. Adv. Drug Deliv. Rev.51, 127–141 (2001).
   PubMed Web of Science ®Google Scholar
• Valiante NM, O'Hagan DT, Ulmer JB. Innate immunity and biodefence vaccines. Cell Microbiol.5, 755–760 (2003).
   PubMed Web of Science ®Google Scholar
• Rynkiewicz D, Rathkopf M, Ransom J et al. Marked enhancement of antibody response to anthrax vaccine adsorbed with CpG 7909 in healthy volunteers. ICAAC (2005) (Abstract LB-25).
   Google Scholar
• Sparwasser T, Koch E, Vabulas RM et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol.28, 2045–2054 (1998).
   PubMed Web of Science ®Google Scholar
• Roman M, Martin-Orozco E, Goodman JS et al. Immunostimulatory DNA sequences function as T helper-1 promoting adjuvants. Nat. Med.3, 849–854 (1997).
   Google Scholar
• Oishi K, Koles NL, Guelde G, Pollack M. Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity. J. Infect. Dis.165, 34–45 (1992).
   PubMed Web of Science ®Google Scholar